Clinical investigators from the CURE trial of Plavix (clopidogrel) in acute coronary syndrome "are working actively to get a study published in the New England Journal of Medicine, which we are hopeful could happen in the next couple of months," Bristol's Lane reports. "FDA is keenly interested in the study and working with us," he says. Bristol and Sanofi-Synthelabo plan "to file sometime this fall, and hope that we will get a very quick review." The initial findings of the trial, showing a 20% reduction in the risk of heart attack, stroke and cardiovascular death, were released in March
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth